Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004939|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 24, 2005
I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.
|Condition or disease||Intervention/treatment||Phase|
|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating||Drug: ,4-diaminopyridine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||34 participants|
|Study Start Date :||August 1996|
|Study Completion Date :||August 1996|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004939
|Study Chair:||Anthony J. Windebank||Mayo Clinic|